Back to results
US 2017/0000730 A1Published application
Ophthalmic drug delivery method
OwnerGholam A. Peymaninventor
Life of this patent
Estimating the term…
Abstract
A method to provide a therapeutic agent to an eye of a patient by implanting or inject a device that stably fits a particular location or position in the eye. The method thus provides agent inside the eye for a longer duration of agent release over a space-occupying area inside the eye.
Claims31
A method of treatment comprising
- providing a ROCK inhibitor to treat at least one of an ocular or neurodegenerative disorder using an implant device placed by implanting or an explant device placed by explanting in an eye of the patient in need of treatment, the device 15 mm to 60 mm in length;
- deformable;
- containing a ROCK inhibitor in at least one of a mucophilic preparation or nanoparticles or microparticles with a cell penetrating peptide;
- shaped to stably fit a suprachoroidal or subretinal position in the eye choroid , or on the lens zonules, or over the sclera under the conjunctiva;
- sized to occupy the choroidal space inside the eye, or the space on the lens zonules, or over the sclera, to provide a relatively longer duration of ROCK inhibitor release over a relatively larger space-occupying area inside the eye;
- and
- implanting or explanting the device in the eye.
4 more elements
A treatment method comprising providing to a patient in need thereof a non-toxic dose of a ROCK inhibitor by a method selected from the group consisting of
- injecting into an eye of the patient at a site selected from the group consisting of through the pars plana, in the vitreous cavity, in an intra-retinal space, in a sub-retinal space, in the choroid and combinations thereof;
- or
- topically applying to the eye of the patient in a formulation selected from the group consisting of nanoparticles, dendrimers, aptamers, micelles, and combinations thereof.
A method of treatment comprising
- providing an anti-glaucoma agent to treat glaucoma using a device implantable in an eye of the patient in need of treatment, the device 5 mm to 60 mm in length;
- deformable;
- containing an anti-glaucoma agent in at least one of a mucophilic preparation or nanoparticles or microparticles with a cell penetrating peptide, optionally in a formulation selected from the group consisting of a solution, a polymer, an implant, microparticles or nanoparticles, and combinations thereof, further comprising poly(amidoamine) (PAMAM), poly(amidoamine-organosilicon) (PAMAMOS), poly(propyleneimine) (PPIO), poly(caprolactone), poly(lactic acid) (PLA), polylactic-co-glycolic acid (PLGA), tecto, multilingual, chiral, hybrid, amphiphilic, micellar, multiple antipen peptide, and Frechet-type dendrimers;
- functionalized microparticles or nanoparticles with an antibody and/or a ligand for a receptor or covalent coupling to one or more of cell penetrating peptides (CPP), arginine-CPP, cysteine-CPP, polyethylene glycol (PEG), biotin-streptavadin, and/or acetyl cysteine ;
- shaped to stably fit in the subconjunctival space anterior or posterior to the insertion of the eye muscles as a string to release the agent through the sclera to provide a relatively longer duration of anti-glaucoma agent release over a relatively larger space-occupying area inside the eye;
- and
- implanting the device in the eye,
4 more elements
A method of treatment comprising
- providing stem cells to treat at least one of an ocular or neurodegenerative disorder using an implant device placed by implanting or an explant device placed by explanting in an eye of the patient in need of treatment, the device 5 mm to 60 mm in length;
- deformable;
- containing stem cells in at least one of a mucophilic preparation or nanoparticles or microparticles with a cell penetrating peptide;
- shaped to stably fit a suprachoroidal or subretinal position in the eye choroid, or on the lens zonules, or over the sclera under the conjunctiva;
- sized to occupy the choroidal space inside the eye, or the space on the lens zonules, or over the sclera, to provide a relatively longer duration of stem cell release over a relatively larger space-occupying area inside the eye;
- and
- implanting or explanting the device in the eye.
4 more elements
Dependencies are inferred from the claim text.